ABSTRACT
Background In vitro studies suggest that casein coagulation of milk is influenced by its mineral composition, and may therefore affect the dynamics of protein digestion, gastric emptying and appearance of amino acids (AA) in the blood, but this remains to be confirmed in vivo.
Objective This study aimed to compare gastrointestinal digestion between two milks with the same total calcium content but different casein mineralization (CM).
Design Fifteen males (age 30.9±13.8 y, BMI 22.5±2.2 kg/m2) participated in this randomized cross-over study with two treatments. Participants underwent gastric magnetic resonance imaging (MRI) scans at baseline and every 10 min up to 90 min after consumption of 600 ml milk with low or high CM. Blood samples were taken at baseline and up to 5 hours postprandially. Primary outcomes were postprandial plasma AA concentrations and gastric emptying rate. Secondary outcomes were postprandial glucose and insulin levels, gastric coagulation as estimated by image texture metrics, and appetite ratings.
Results Gastric content volume over time was similar for both treatments. However, gastric content image analysis suggested that the liquid fraction emptied quicker in the high CM milk, while the coagulum emptied slower. Relative to high CM, low CM showed earlier appearance of AAs that are more dominant in casein, such as proline (MD 4.18 µmol/L, 95%CI [2.38-5.98], p<0.001), while there was no difference in appearance of AAs that are more dominant in whey protein, such as leucine. The image texture metrics homogeneity and busyness differed significantly between treatments (MD 0.007, 95%CI [0.001, 0.012], p=0.022; MD 0.005, 95%CI [0.001, 0.010], p=0.012) likely because of a reduced coagulation in the low CM milk.
Conclusions Mineral composition of milk can influence postprandial serum AA kinetics, likely due to differences in coagulation dynamics.
Competing Interest Statement
This study was funded by FrieslandCampina and TL and TH are employed by FrieslandCampina. All other authors declare no further conflict of interest.
Clinical Trial
Registered with the Dutch Trial Registry under number NL8959 accessible through https://trialsearch.who.int/Trial2.aspx?TrialID=NL8959
Funding Statement
This study was funded by FrieslandCampina
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Wageningen University (METC-WU) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
